Treace to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI) will announce its fourth quarter and full year 2022 financial results on March 7, 2023, following the market close. A conference call will take place at 4:30 pm ET to discuss these results. Treace focuses on surgical treatments for hallux valgus (bunions) through its proprietary Lapiplasty® 3D Bunion Correction™ Procedure. Approximately 65 million Americans are affected by bunions, with an estimated 1.1 million being surgical candidates annually. The company aims to improve surgical management standards for bunion deformities.

PONTE VEDRA, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Tuesday, March 7, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.com
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.com

 

FAQ

When will Treace Medical Concepts release its 2022 financial results?

Treace Medical Concepts will release its financial results for the fourth quarter and full year of 2022 on March 7, 2023.

What is the focus of Treace Medical Concepts?

Treace Medical Concepts specializes in surgical treatments for hallux valgus (bunions) with its innovative Lapiplasty® 3D Bunion Correction™ Procedure.

How many Americans are affected by bunions?

Approximately 65 million Americans are affected by bunions, with around 1.1 million being annual surgical candidates.

What will be discussed in the Treace Medical Concepts conference call?

The conference call will discuss the financial results for the fourth quarter and full year of 2022.